Longeveron (LGVN) Interest Expenses (2020 - 2026)
Longeveron (LGVN) posted quarterly Interest Expenses of $770000.0 for Q1 2026, down 41.44% year-over-year from $1.3 million in Q1 2025, and down 9.73% quarter-over-quarter from $853000.0 in Q4 2025.
Longeveron (LGVN) Interest Expenses (2020 - 2026) Analysis & Trends
Longeveron's Interest Expenses history runs 7 years deep, the most recent figure standing at $770000.0 for Q1 2026.
- In Q1 2026, Interest Expenses fell 41.44% year-over-year to $770000.0; the TTM figure through Mar 2026 stood at $770000.0 (down 41.44% YoY), while the FY2025 annual figure was $1.1 million, down 94.15% from the prior year.
- Interest Expenses for Q1 2026 stood at $770000.0, down from $853000.0 in the prior quarter.
- The five-year high for Interest Expenses was $38.0 million in Q1 2023, with the low at -$12000.0 in Q4 2022.
- The 5-year median for Interest Expenses is $702000.0 (2022), against an average of $2.8 million.
- The sharpest annual moves came in 2023 and 2024: Interest Expenses jumped 5313.11% in 2023, then slumped 99.41% in 2024.
- Longeveron's Interest Expenses stood at -$12000.0 in 2022, then soared by 358.33% to $31000.0 in 2023, then surged by 3012.9% to $965000.0 in 2024, then decreased by 11.61% to $853000.0 in 2025, then decreased by 9.73% to $770000.0 in 2026.
- Business Quant data shows LGVN's Interest Expenses at $770000.0 in Q1 2026, $853000.0 in Q4 2025, and $1.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Mn |
| Jun 30, 2026 | 1.33 Mn |
| Mar 31, 2026 | 770,000.00 |
| Mar 31, 2026 | 770,000.00 |
| Dec 31, 2025 | 853,000.00 |
| Dec 31, 2025 | 853,000.00 |
| Sep 30, 2025 | 1.47 Mn |
| Sep 30, 2025 | 1.47 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Mar 31, 2025 | 1.32 Mn |
| Dec 31, 2024 | 965,000.00 |
| Dec 31, 2024 | 965,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Sep 30, 2024 | 224,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 224,000.00 |
| Mar 31, 2024 | 224,000.00 |